CH 5132799

Drug Profile

CH 5132799

Alternative Names: CH5132799; PA-799

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Chugai Pharma Europe
  • Developer Chugai Pharma Europe; The Institute of Cancer Research
  • Class Antineoplastics
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 28 Nov 2016 CH 5132799 licensed to Berlin Chemie worldwide
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Monotherapy) in United Kingdom (PO)
  • 01 Nov 2014 Efficacy, safety and adverse event data from a phase I trial in solid tumours released by the Institute of Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top